Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: Zooming in on cytokeratin 18 fragments

Biomarkers in Medicine

Volumn 4, Issue 5, 2010, Pages 743-745

  Yilmaz, Yusuf ^a   Kurt, Ramazan ^a   Kalayci, Cem ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

alanine aminotransferase; apoptosis; nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; CYTOKERATIN 18; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M30; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; APOPTOSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; HUMAN; LETTER; LIVER CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS;

ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; APOPTOSIS; BIOLOGICAL MARKERS; CASPASE 3; CASPASE 8; FATTY LIVER; HUMANS; KERATIN-18;

EID: 77958072786     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.65     Document Type: Letter

References (26)

1. Wieckowska A, McCullough AJ, Feldstein AE: Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46, 582-589 (2007).
2. Schindhelm RK, Diamant M, Dekker JM et al.: Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to Type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab. Res. Rev. 22, 437-443 (2006).
3. Lee JK, Shim JH, Lee HC et al.: Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 51, 1577-1583 (2010).
4. Calvaruso V, Craxì A: Implication of normal liver enzymes in liver disease. J. Viral Hepat. 16, 529-536 (2009).
5. Prati D, Taioli E, Zanella A et al.: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 137, 1-10 (2002).
6. Yang RZ, Park S, Reagan WJ et al.: Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity. Hepatology 49, 598-607 (2009).
7. Jadhao SB, Yang RZ, Lin Q et al.: Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology 39, 1297-1302 (2004).
8. Fracanzani AL, Valenti L, Bugianesi E et al.: Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48, 792-798 (2008).
9. Wieckowska A, Feldstein AE: Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis. 28, 386-395 (2008).
10. Hübscher SG: Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 16, 1107-1115 (2004).
11. Canbakan B, Senturk H, Canbakan M et al.: Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? Biomark. Med. 4(2), 205-214 (2010).
12. Feldstein AE, Canbay A, Angulo P et al.: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437-443 (2003).
13. Yilmaz Y: Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment. Pharmacol. Ther. 30, 1103-1109 (2009).
14. Yilmaz Y, Kedrah AE, Ozdogan O: Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J. Gastroenterol. 15, 4387-4391 (2009).
15. Yilmaz Y, Dolar E, Ulukaya E et al.: Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J. Gastroenterol. 14, 837-844 (2007).
16. Vos MB, Barve S, Joshi-Barve S et al.: Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 47, 481-485 (2008).
17. Yilmaz Y, Ulukaya E, Dolar E: Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. Hepatology 49, 697 (2009).
18. Duan WR, Garner DS, Williams SD et al.: Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J. Pathol. 199, 221-228 (2003).
19. Younossi ZM, Jarrar M, Nugent C et al.: A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 18, 1430-1437 (2008).
20. Feldstein AE, Wieckowska A, Lopez AR et al.: Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50, 1072-1078 (2009).
21. Simopoulos C, Tsaroucha AK, Asimakopoulos B et al.: Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study. BMC Gastroenterol. 8, 14 (2008).
22. Barak V, Goike H, Panaretakis KW, Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin. Biochem. 37, 529-540 (2004).
23. Senturk T, Aydinlar A, Yilmaz Y et al.: Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. Coron. Artery Dis. 20, 494-498 (2009).
24. de Haas EC, di Pietro A, Simpson KL et al.: Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10, 1041-1048 (2008).
25. Emanuele E: Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 48, 2086-2087 (2008).
26. Yilmaz Y, Ulukaya E, Dolar E: A "biomarker biopsy" for the diagnosis of NASH: promises from CK-18 fragments. Obes. Surg. 18, 1507-1508 (2008).